{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T01:32:17Z","timestamp":1775611937505,"version":"3.50.1"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,10,18]],"date-time":"2022-10-18T00:00:00Z","timestamp":1666051200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Crizotinib is an oral selective small-molecular tyrosine kinase inhibitor (TKI) that suppress the activity of anaplastic lymphoma kinase (ALK) and ROS1 kinases, as well as mesenchymal-epithelial transition. The cumulative clinical trials in patients with advanced ALK- or ROS1-rearrangement NSCLC indicate that crizotinib has significant antitumor activity and a tolerable safety profile, with mild or moderate adverse events of visual disorders, diarrhea, nausea, and vomiting. As with other TKIs, however, the occurrence of crizotinib-related interstitial lung disease (crizotinib-ILD) remains a major clinical dilemma that can lead to the permanent discontinuation of TKI during cancer treatment. When there is no suitable alternative therapy for patients who develop crizotinib-ILD, some clinicians have reported successful crizotinib retreatment in cases of ALK-rearrangement NSCLC. Unfortunately, there are no specific guidelines for the treatment or retreatment of TKI-related ILD. We herein report the first successful crizotinib retreatment after crizotinib-ILD in a patient with ROS1-rearranged NSCLC, and suggest a retreatment strategy after crizotinib-ILD based on a literature review.<\/jats:p>","DOI":"10.3389\/fonc.2022.900966","type":"journal-article","created":{"date-parts":[[2022,10,18]],"date-time":"2022-10-18T08:55:17Z","timestamp":1666083317000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy of crizotinib retreatment after crizotinib-related interstitial lung disease in a patient with ROS1-rearranged advanced lung adenocarcinoma: A case report and potential crizotinib retreatment strategy"],"prefix":"10.3389","volume":"12","author":[{"given":"Woo Kyung","family":"Ryu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyungkeun","family":"Cha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mi Hwa","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung Soo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeong-Seok","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucia","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyung-Hee","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hae-Seong","family":"Nam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,10,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1406766","article-title":"Crizotinib in Ros1-rearranged non-Small-Cell lung cancer","volume":"371","author":"Shaw","year":"2014","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.5587","article-title":"Phase ii study of crizotinib in East Asian patients with Ros1-positive advanced non-Small-Cell lung cancer","volume":"36","author":"Wu","year":"2018","journal-title":"J Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.35.6345","article-title":"Ros1 rearrangements define a unique molecular class of lung cancers","volume":"30","author":"Bergethon","year":"2012","journal-title":"J Clin Oncol"},{"key":"B4","unstructured":"Fda expands use of xalkori to treat rare form of advanced non-small cell lung cancer2016"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyu074","article-title":"Successful crizotinib rechallenge after crizotinib-induced interstitial lung disease","volume":"44","author":"Tachihara","year":"2014","journal-title":"Jpn J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1093\/omcr\/omu004","article-title":"Acute interstitial lung disease in a patient with anaplastic lymphoma kinase-positive non-Small-Cell lung cancer after crizotinib therapy","volume":"2014","author":"Maka","year":"2014","journal-title":"Oxf Med Case Rep"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1159\/000366516","article-title":"Successful crizotinib rechallenge after crizotinib-induced organizing pneumonia in anaplastic lymphoma kinase-rearranged non-small cell lung cancer","volume":"7","author":"Asai","year":"2014","journal-title":"Case Rep Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2013.12.004","article-title":"Successful crizotinib rechallenge after crizotinib-induced interstitial lung disease in patients with advanced non-Small-Cell lung cancer","volume":"15","author":"Asai","year":"2014","journal-title":"Clin Lung Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e318293dfc1","article-title":"Successful crizotinib retreatment after crizotinib-induced interstitial lung disease","volume":"8","author":"Yanagisawa","year":"2013","journal-title":"J Thorac Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics11122201","article-title":"A preliminary study on the prognostic impact of neutrophil to lymphocyte ratio of the bronchoalveolar lavage fluid in patients with lung cancer","volume":"11","author":"Ryu","year":"2021","journal-title":"Diagnos (Basel)"},{"key":"B11","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s13045-020-00977-0","article-title":"Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001-2020)","volume":"13","author":"Huang","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1006448","article-title":"Anaplastic lymphoma kinase inhibition in non-Small-Cell lung cancer","volume":"363","author":"Kwak","year":"2010","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.21037\/jtd.2019.07.44","article-title":"Efficacy and safety of crizotinib in patients with Ros1 rearranged non-small cell lung cancer: A retrospective analysis","volume":"11","author":"Masuda","year":"2019","journal-title":"J Thorac Dis"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.43.3730","article-title":"Severe acute interstitial lung disease after crizotinib therapy in a patient with Eml4-Alk-Positive non-Small-Cell lung cancer","volume":"31","author":"Tamiya","year":"2013","journal-title":"J Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2017.10.008","article-title":"Lung toxicity in non-Small-Cell lung cancer patients exposed to alk inhibitors: Report of a peculiar case and systematic review of the literature","volume":"19","author":"Pellegrino","year":"2018","journal-title":"Clin Lung Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2017.03.004","article-title":"Interstitial lung disease associated with crizotinib in patients with advanced non-small cell lung cancer: Independent review of four profile trials","volume":"18","author":"Yoneda","year":"2017","journal-title":"Clin Lung Cancer"},{"key":"B17","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s12890-018-0682-9","article-title":"Fatal interstitial lung disease associated with crizotinib pathologically confirmed by percutaneous lung biopsy in a patient with Ros1-rearranged advanced non-Small-Cell lung cancer: A case report","volume":"18","author":"Wu","year":"2018","journal-title":"BMC Pulm Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201002-0188OC","article-title":"Egfr tyrosine kinase inhibition worsens acute lung injury in mice with repairing airway epithelium","volume":"183","author":"Harada","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0000000000000577","article-title":"Crizotinib associated with ground-glass opacity predominant pattern interstitial lung disease: A retrospective observational cohort study with a systematic literature review","volume":"10","author":"Crequit","year":"2015","journal-title":"J Thorac Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2021-1102","article-title":"Effectiveness of crizotinib versus entrectinib in Ros1-positive non-Small-Cell lung cancer using clinical and real-world data","volume":"18","author":"Tremblay","year":"2022","journal-title":"Future Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2022.100332","article-title":"Long-term efficacy and safety of entrectinib in Ros1 fusion-positive nsclc","volume":"3","author":"Drilon","year":"2022","journal-title":"JTO Clin Res Rep"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30690-4","article-title":"Entrectinib in Ros1 fusion-positive non-Small-Cell lung cancer: Integrated analysis of three phase 1-2 trials","volume":"21","author":"Drilon","year":"2020","journal-title":"Lancet Oncol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.17.00026","article-title":"Drug-related pneumonitis in the era of precision cancer therapy","volume":"1","author":"Nishino","year":"2017","journal-title":"JCO Precis Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.900966\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,18]],"date-time":"2022-10-18T08:55:20Z","timestamp":1666083320000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.900966\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,18]]},"references-count":23,"alternative-id":["10.3389\/fonc.2022.900966"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.900966","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,18]]},"article-number":"900966"}}